Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENT (Details Textual) - USD ($)	1 Months Ended
SUBSEQUENT EVENT (Details Textual) - USD ($)	Oct. 31, 2015	Sep. 30, 2015
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		6,597,483
Subsequent Event [Member]
Registered Direct Offering Shares Of Common Stock	1,017,272
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	482,728
Offering Price Per Share	$ 2.20
Pre Funded Price Per Share	$ 2.20
Description of Equity Financing	Similarly, from and after the time the stockholder approval has been obtained until the Company completes an equity financing with gross proceeds of at least $10.0 million, if the Company issues shares of common stock or common stock equivalents for a purchase price less than the then-effective exercise price for the Series A Warrants, the exercise price of the Series A Warrants will be lowered to equal that lower price.
Subsequent Event [Member] \| Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	37,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.83
Warrants and Rights Outstanding	$ 61,000
Subsequent Event [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.83
Gross Proceeds From Offering	$ 3,300,000
Net Proceeds From Offering	$ 2,868,000